INCYTE
Incyte 2014 Annual Report
to Stockholders
Jakafi® (ruxolitinib)
Prescribing Information

is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary small molecule drugs, primarily for oncology.

News
Incyte Reports 2015 Second-Quarter Financial Results and Updates Shareholders on Key Clinical Programs
Incyte and Vanderbilt University Medical Center Establish Multi-Year Oncology Research Alliance
Lilly and Incyte unveil detailed data on two pivotal studies of baricitinib in rheumatoid arthritis
Jakafi® (ruxolitinib)
IncyteCARES
Connecting to Access, Reimbursement, Education and Support
To learn more, click here